University of Texas at Austin

utexas.edu

Total trials

348

Active

93

Phase 3

9

Total enrollment

59,608

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 10 of 10 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Suzetrigine1
Sertraline1
Gabapentin Enacarbil1
Lumateperone 42 mg1
Anticoagulants1
Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Crohn's1
Brain state-dependent paired corticomotoneuronal stimulation1
Psilocybin1
Low-dose psilocybin1
Ketamine only1

Next readouts

  • 2022-08-31
  • 2025-04-01
  • 2026-05
  • 2026-12
  • 2027-07-15
  • 2028-02
  • 2029-12-31
  • 2030-01
  • 2030-07

Top conditions

  • Depression21
  • Anxiety9
  • Healthy9
  • Social Anxiety Disorder7
  • Metabolic Syndrome7
  • Major Depressive Disorder7
  • Hypertension7
  • Obesity6

Frequently asked questions about University of Texas at Austin

How many clinical trials does University of Texas at Austin have on ClinicalTrials.gov?
University of Texas at Austin is listed as the lead sponsor on 348 clinical trials in ClinicalTrials.gov, 93 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Texas at Austin's trials are in Phase 3?
9 of University of Texas at Austin's trials are in Phase 3, spread across 10 active drug programs.
What therapeutic areas does University of Texas at Austin focus on?
University of Texas at Austin's most-studied conditions on ClinicalTrials.gov are Depression, Anxiety, Healthy, Social Anxiety Disorder, Metabolic Syndrome.
When are University of Texas at Austin's next clinical trial readouts?
University of Texas at Austin has 9 upcoming primary-completion readouts tracked here; the soonest is “Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease”, expected around 2022-08-31.